Australian Institute of Health and Welfare (2022) Alcohol, tobacco & other drugs in Australia, AIHW, Australian Government, accessed 10 August 2022.
Australian Institute of Health and Welfare. (2022). Alcohol, tobacco & other drugs in Australia. Retrieved from https://pp.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Alcohol, tobacco & other drugs in Australia. Australian Institute of Health and Welfare, 20 April 2022, https://pp.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2022 Aug. 10]. Available from: https://pp.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare (AIHW) 2022, Alcohol, tobacco & other drugs in Australia, viewed 10 August 2022, https://pp.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Get citations as an Endnote file:
Supply reduction involves ‘preventing, stopping, disrupting or otherwise reducing the production and supply of illegal drugs; and controlling, managing and/or regulating the availability of legal drugs’ (DoH 2017b).
Information on the availability of alcohol, tobacco and other drugs in Australia comes from research with people who use drugs, seizure data from law enforcement agencies, wastewater analysis and information collated from international sources in relation to drug manufacturing and importation.
The consumption of alcohol and tobacco by adults is legal in Australia. Almost 1 in 2 (45%) Australians aged 14 years and over approved of regular adult consumption of alcohol compared with 15.4% who approved of regular tobacco use (AIHW 2020). Alcohol and tobacco products are available for purchase; however, there are a number of strict regulations that control their supply. Specific supply reduction interventions include:
Pharmaceutical drugs are available over-the-counter (OTC) or from a registered health practitioner for the treatment of illness or injury. Their supply by health practitioners is subject to strict controls in relation to quantity supplied and directions for consumption, including the provision of advice to the consumer on restricting the use of these drugs in combination with alcohol and other licit and illicit drugs (TGA 2018).
When pharmaceutical drugs are used for non-medical purposes, the drugs can be diverted or channelled from the legal supply system to the illegal marketplace for misuse. This process of diversion may occur in a number of ways such as sharing between family and friends, theft, prescription forgery, doctor shopping, illegal sale and overprescribing by health practitioners. Policies aimed at reducing the supply of pharmaceutical drugs for non-medical use in Australia, include:
In 2016, cannabis became available medicinally in Australia for specific patient groups under strict medical supervision. Other than in these limited circumstances, the cultivation, possession and supply of cannabis remains prohibited in Australia (DoH 2017a).
The possession and supply of other illicit drugs such as cannabis, meth/amphetamine, heroin and cocaine are prohibited in Australia. Illicit drugs are commonly sourced for use from friends and relatives, dealers and online (AIHW 2020). Research with people who use drugs suggest illicit drugs are readily available in Australia.
The Illicit Drug Reporting System (IDRS) is an annual survey of people who inject drugs, and includes questions about the availability of illicit drugs. The latest IDRS data were collected from June–July 2021.
In 2021, most IDRS respondents indicated that heroin, cocaine and cannabis were ‘easy’ or ‘very easy’ to obtain (Sutherland al. 2021b). Additionally, over 4 in 5 (86%) respondents reported that meth/amphetamine was ‘easy’ or ‘very easy’ to obtain, an increase from 48% in 2020 (Sutherland et al. 2021b).
The Ecstasy and Related Drugs Reporting System (EDRS) is an annual survey of people who regularly use ecstasy and other stimulants, and includes questions on the availability of illicit drugs. The latest EDRS data were collected from April–August 2021.
In 2021, most EDRS respondents indicated that ecstasy, cocaine and ketamine were ‘easy’ or ‘very easy’ to obtain.
Due to COVID-19 restrictions being imposed in various jurisdictions during data collection periods for both the IDRS and the EDRS, interviews in 2020 and 2021 were delivered face-to-face as well as via telephone. This change in methodology should be considered when comparing data from the 2020 and 2021 samples relative to previous years.
The National Drug and Alcohol Research Centre (NDARC) Drug Trends program monitors trends in drugs across Australia. Information is collected from a range of sources including annual interviews with people across Australia who regularly inject drugs through the Illicit Drug Reporting System (IDRS) and those who regularly use ecstasy or other stimulants through the Ecstasy and Related Drugs Reporting System (EDRS). The IDRS and EDRS sample is a sentinel group that provides information on patterns of drug use and market trends.
The IDRS consists of annual interviews with people who regularly inject drugs, participants are recruited from all capital cities of Australia. The monitoring system is intended to provide trends and identify emerging issues in illicit drug markets (Sutherland et al. 2021b).
The EDRS uses a similar methodology to the IDRS in that it uses annual interviews with people who regularly use ecstasy and other stimulants. The EDRS monitors the price, purity and availability of ‘ecstasy’ and other drugs such as methamphetamine, cocaine, gamma-hydroxybutyrate (GHB), d-lysergic acid (LSD), 3,4-methylendioxyamphetamine (MDA) and ketamine. It also examines trends in the use and harms of these drugs (Sutherland et al. 2021b).
It is important to note that the results from the IDRS and EDRS surveys are not representative of people who use illicit drugs or the general population. The aim of these data are intended to provide evidence that is indicative of emerging issues that warrant further monitoring.
Further information about the Drug Trends program.
There have been fluctuations in the illicit drug market at certain times. For example, in the early 2000s there was a widespread heroin shortage in Australia, which followed a period of unprecedented heroin availability in Australia in the late 1990s. The heroin shortage has been attributed to a range of factors, including high purity and low profit margins for dealers, along with a number of law enforcement seizures (Degenhardt, Day & Hall 2004).
Examples of supply reduction initiatives to limit the availability of illicit drugs include:
The Australian Criminal Intelligence Commission (ACIC) collects national illicit drug seizure data annually from federal, state and territory police services, including the number and weight of seizures to inform the Illicit Drug Data Report (IDDR). According to the 2019–20 IDDR, there were 121,274 national illicit drug seizures in 2019–20, which is equivalent to around one seizure every 4.5 minutes. There has been an overall increase in the number of seizures over the last decade from 69,595 in 2010–11, with an 8% increase compared with the previous year (Figure HARM3). Cannabis (51%) and amphetamine-type stimulants (ATS; 32%) accounted for the greatest proportion of national illicit drug seizures in 2019–20. The number of cannabis seizures increased 11% in 2019–20 and ATS seizures increased 2% compared with 2018–19 (ACIC 2021).
The weight of illicit drugs seized nationally was 38.5 tonnes in 2019–20, an increase from 26.6 tonnes in 2018–19 (a 45% increase). The weight of illicit drugs seized in 2019–20 increased from the previous year across all drug types except cocaine, which decreased by 4%. Illicit drugs classified as other and unknown accounted for the greatest proportion of the weight of illicit drugs seized in 2019–20 (34%) followed by ATS (33%), cannabis (28%), cocaine (4%) and heroin and other opioids (1%). Overall, there has been a 314% increase in the weight of illicit drugs seized over the last decade (9.3 tonnes in 2010–11) (Figure HARM3).
This figure shows that the number of seizures has increased from 2009–10 to 2018–19. In 2018–19, most seizures were for cannabis (56,491 seizures) and amphetamine-type stimulants (38,250 seizures).
Wastewater analysis provides estimates of drug usage in a population by measuring concentrations of drug metabolites (excreted into the sewer system after consumption) in wastewater samples. The National Wastewater Drug Monitoring Program (NWDMP) of the Australian Criminal Intelligence Commission (ACIC) monitors selected substances of concern in the most populated regions of Australia (ACIC 2021).
Fifty-eight wastewater treatment sites participated nationally in the August 2021 collection (Report 15 of the NWDMP), with 22 sites located in capital cities and 36 in regional locations. This covers around 57% of the Australian population, or about 13.3 million people. Of the substances monitored by the NWDMP that have available dose data, alcohol and nicotine remain the highest consumed substances. Methylamphetamine is the most consumed illicit drug (ACIC 2022).
Results from the National Wastewater Drug Monitoring Program (NWDMP) indicate that methylamphetamine is the highest consumed illicit drug in Australia, for substances monitored by the program that have available dose data. This analysis excludes cannabis, the drug found to have the highest self-reported level of recent consumption (11.6%) in the 2019 National Drug Strategy Household Survey (NDSHS). The ACIC is seeking to obtain a reliable dose figure for cannabis. The NDSHS results also indicate higher proportions of recent use for cocaine (4.2%) and ecstasy (3.0%) than for meth/amphetamine (1.3%) (Table S2.32).
It is important to note the different methodologies and sample coverage for the collections. The NWDMP measures the level of consumption of the specified substances within the community. The NDSHS findings are based on self-reported survey data from people aged 14 and over who live in residential dwellings; this excludes people living in non-private dwellings, institutions (such as prisons and drug and alcohol rehabilitation centres) and people experiencing homelessness. Results are not verified by blood tests or other screening measures and estimates of illicit drug use in the NDSHS are likely to be underestimates of actual use. In addition, some non-response bias is expected, but this bias has not been measured.
Differences in the frequency of consumption of different drugs may account, in part, for the higher level of methylamphetamine consumption reported in the NWDMP. The NDSHS results indicate that a higher proportion of people who recently used meth/amphetamine (16.9%) reported using it at least once a week or more, and this increased to 29% among those who used crystal/ice as their main form of meth/amphetamines. In comparison, 6.7% of people who used ecstasy and 4.5% of people who used cocaine reported using them at least once a week or more (AIHW 2020).
For further information, see:
The ACIC has assessed the relationship between supply and demand in the Australian methylamphetamine market by overlaying data from the NWDMP with illicit drug seizure data. The key findings indicate that large seizures have an impact on consumption, particularly in capital cities. The impact is not immediate and usually lasts between 2 to 4 months (ACIC 2019).
ACIC (Australian Criminal Intelligence Commission) 2019. Methylamphetamine supply reduction—measures of effectiveness. Canberra: ACIC. Viewed 14 October 2019.
ACIC 2021. Illicit Drug Data Report 2019–20. Canberra: ACIC. Viewed 20 October 2021.
ACIC 2021. National Wastewater Drug Monitoring Program Report 13. Canberra: ACIC. Viewed 18 August 2021.
ACIC 2022. National Wastewater Drug Monitoring Program Report 15. Canberra: ACIC. Viewed 18 March 2022.
AIHW (Australian Institute of Health and Welfare) 2020. National Drug Strategy Household Survey 2019. Drug statistics series no. 32. Cat. no. PHE 270. Canberra: AIHW. Viewed 16 July 2020.
Degenhardt L, Day C & Hall W 2004. The causes, course and consequences of the heroin shortage in Australia. Canberra: National Drug Law Enforcement Research Fund.
DoH (Department of Health) 2017a. Medicinal cannabis. Canberra: Office of Drug Control. Viewed 4 January 2018.
DoH 2017b. National Drug Strategy 2017–2026. Canberra: Australian Government. Viewed 12 January 2018.
Sutherland R, Peacock A, Karlsson A, Uporova J, Price O, Chandrasena U, Swanton R, Gibbs D, Bruno R, Wilson Y, Dietze P, Hall C, Eddy S, Lenton S, Grigg J, Salom C, Daly C, Thomas N, Juckel J, Degenhardt L, Farrell M. 2021a. Australian Drug Trends 2021: Key Findings from the National Ecstasy and Related Drugs Reporting System (EDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney.
Sutherland R, Uporova J, Chandrasena U, Price O, Karlsson A, Gibbs D, Swanton R, Bruno R, Dietze P, Lenton S, Salom C, Daly C, Thomas N, Juckel J, Agramunt S, Wilson Y, Woods E, Moon C, Degenhardt L, Farrell M and Peacock A. 2021b. Australian Drug Trends 2021: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney.
TGA (Therapeutic Goods Administration) 2018. Regulation basics. Viewed 2 February 2018.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.